A new analysis suggests that the effectiveness of GLP-1 receptor mono-agonists in obesity treatment varies significantly with drug type and dosage, underscoring the importance of personalised therapy for improved cardiometabolic outcomes.
A new analysis of GLP-1 medicines suggests that both the choice of drug and the dose used can make a measurable difference to heart and metabolic outcomes, strengthening the case that obesity treatment may need to be tailored more closely to a patient’s broader cardiometabolic profile. The work, published in Diabetes, Obesity and Metabolism and based on 19 randomised controlled trials involving 13,117 adults with overweight or obesity, compared oral and injectable GLP-1 receptor mono-agonists across several markers rather than weight loss alone.
Researchers from the University of Pennsylvania, Yale School of Medicine and UT Southwestern Medical Centre built a composite Cardiometabolic Efficacy Index to rank treatments across seven measures: weight loss, triglycerides, HDL cholesterol, LDL cholesterol, waist circumference, HbA1c and systolic blood pressure. According to the published abstract, semaglutide at 7.2 mg scored highest at 0.86, followed by oral orforglipron at 36 mg on 0.68 and semaglutide at 2.4 mg on 0.66. All three achieved placebo-adjusted weight reductions of at least 10%, and the rankings were broadly similar whether or not participants had type 2 diabetes.
The study also found that the strongest overall performer was not always the best on every individual measure. The full paper indicates that orforglipron ranked particularly well for blood sugar, HDL cholesterol and systolic blood pressure, while semaglutide showed the largest effects on LDL cholesterol, total body weight and waist circumference. That matters because many people taking these medicines are not only trying to lose weight, but also aiming to improve cholesterol, glucose control or blood pressure at the same time.
At the same time, the findings should be treated as informative rather than decisive. This was a network meta-analysis, which combines indirect comparisons across separate trials rather than testing the medicines head-to-head in a single study. The analysis covered GLP-1 mono-agonists only, so it does not tell clinicians how tirzepatide or other dual and triple incretin drugs would compare. The index itself was created by the authors for this project and has not been validated as a clinical decision-making tool.
That limitation is important because treatment choices in the real world are still driven by factors such as insurance coverage, prior authorisation, cost, side effects and availability. The study may nevertheless help frame discussions between patients and prescribers, particularly for people living with more than one cardiometabolic risk factor. A person whose main concern is HbA1c and blood pressure may reasonably prioritise a different drug or dose from someone focused chiefly on weight and waist circumference.
Previous meta-analyses have already suggested that newer incretin drugs can differ meaningfully in efficacy. One recent review found tirzepatide outperformed liraglutide and semaglutide on weight loss in people with obesity without type 2 diabetes, while another found tirzepatide 15 mg was most effective for HbA1c reduction in adults with type 2 diabetes. The newer GLP-1-only analysis does not replace those findings, but it adds a more detailed look at how within-class differences and dose escalation may shape cardiometabolic benefit.
The practical message is modest but clear: these medicines are not interchangeable in every respect, and higher doses often performed better across multiple markers. But the study does not provide a prescribing algorithm, and it does not justify switching or changing treatment without medical advice. For clinicians and patients alike, it is best read as a reminder that obesity pharmacotherapy is becoming more nuanced, not as a final answer on which GLP-1 is best for everyone.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
